日本蓝皮书的介绍及启示

目的：介绍日本仿制药上市后质量动态信息的最新查询途径，为建立我国相关橙皮书提供借鉴。方法：介绍日本蓝皮书的背景、结构和内容，并以熊去氧胆酸片为例，详细介绍日本蓝皮书的使用方法。结果与结论：仿制药质量再评价工作在日本开展了近20年，淘汰了约10%的不合格药品。对于仿制药质量再评价的跟踪和实施、市场抽验及药品质量研讨会有效保证了口服固体仿制药药品质量的一致性和有效性，日本蓝皮书是对该项工作成果的集中系统整理，对我国开展仿制药一致性评价工作具有积极的启示。

Introduction and Inspiration of Japanese Blue Paper

Objective: To introduce the latest query route of dynamic quality information of Japanese postmarket generic drugs and to provide references for the establishment of China orange paper. Methods: The background, structure and content of the Japanese blue paper were introduced. Moreover, how to use the Japanese blue paper was introduced in detail by using ursodeoxycholic acid tablet as an example. Results and Conclusion: It has been nearly 20 years since the re-evaluation of the quality of generic drugs in Japan. About 10% substandard drugs had been withdrawn from the market. As a follow-up of the re-evaluation of the quality of generic drugs, sampling test and drug quality information seminar effectively ensure the consistency and effectiveness of oral solid generic drugs. The Japanese blue paper is a centralized and systematic collection for the results of the work, and has a positive inspiration for the consistency evaluation of the generic drugs in China.